Veraxa as a partner

Enabling breakthrough antibody-based therapies

Our unique suite of technologies enables us to create a series of highly innovative targeted biotherapeutics. We are open to strategic partnership that support our core strategy and increase the value of our growing BiTAC and ADC drug pipeline.

Product partnerships

VERAXA has established a proprietary pipeline of highly innovative drug candidates applying its antibody, antibody-drug conjugate and novel bispecific-targeting capabilities.

Our most advanced project has delivered promising phase-1 clinical trial results and addresses FLT-3, a promising target molecule, which is overexpressed in the majority of AML cancer cells.

R&D alliances

VERAXA is open to collaborate with partners on de novo projects bringing together our innovative suite of technologies with novel target combinations in oncology and potentially other indications.

If you want to learn more about ways to partner with VERAXA, reach out via partnering@veraxa.com or meet us at one of the upcoming conferences.

Companies we've worked with:

If you are interested in partnering with us

We are your partner from target to antibody to ADC. Our unique antibody screening platform and proprietary ADC technology enable us to help you create the best targeted biotherapeutics for your application.

With partnership models tailored to your needs, we can join you at any step of your development journey, whether you are starting out with a target or are looking for a bioconjugation partner.

Get in touch

Meet us at

Oct 15
-
Oct 17
2024
Festival of Biologics 2024, Basel
Oct 9
-
Oct 9
2024
BioRN Annual Conference 2024, Heidelberg
Aug 20
-
Aug 22
2024
2nd ADC Linker & Conjugation Summit, Boston, USA
Aug 8
-
Aug 10
2024
2024 Genetic Code Expansion Conference, Corvallis, USA
Jun 3
-
Jun 6
2024
BIO International Convention, USA
Apr 5
-
Apr 10
2024
AACR
Mar 18
-
Feb 20
2024
BIO-Europe Spring
Mar 13
-
Mar 14
2024
World ADC, London